Each extended-release tablet contains 1.08 g of Potassium Citrate.
Pharmacology: Pharmacodynamics: Mechanism of Actions: Potassium Citrate is contained within a porous wax matrix. As this wax matrix is insoluble, it can be eliminated in visible form in the feces. Potassium citrate, however, has been released in the gastrointestinal tract.
For treatment of patients with renal lithiasis and hypocitraturia, chronic formers of calcium oxalate, phosphate calculi; uric acid lithiasis alone or with calcium lithiasis; and renal tubular acidosis with calcium nephrolithiasis.
Patients with Severe Hypocitraturia: Start the treatment with a dose of 60 mEq daily (6 tablets), divided into 3 intakes daily or as prescribed by the physician.
Patients with Mild Hypocitraturia: Start the treatment with dose of 30 mEq daily (3 tablets), divided into 3 intakes daily or as prescribed by the physician.
It is recommended to take the tablets 30 min after meals. Approximately 24 hrs after having started the treatment, make a determination of urinary citrate and pH and adjust the dose in accordance with the needs of the patient. If necessary, the mEq/day (10 tablets) or as prescribed by the physician.
Administration: Should be taken with food. (Take ½ hr after meals. Swallow whole, do not chew/crush).
Symptoms: The long-term administration in patients having a trend to retain potassium may produce hyperpotassemia. In advanced phase, muscular paralysis and cardiovascular collapse may be produced.
Treatment: The recommended treatment in case of hyperpotassemia is IV administration of 10% dextrose solution, containing insulin 10-12 units/1000 ml; correction of the possible acidosis with IV sodium bicarbonate and hemodialysis or peritoneal dialysis.
Renal insufficiency, persistent alkaline urinary infections, obstruction of the urinary tract, hyperpotassemia, adrenal insufficiency, respiratory or metabolic alkalosis, active peptic ulcer, intestinal obstruction, patients submitted to anticholinergics therapy and patients with slow gastric emptying.
In patients with altered potassium excretion mechanism, hyperpotassemia may appear.
In patients with renal insufficiency, there is an increased risk of appearance of hyperpotassemia and for this reason, it is advised not to exceed the recommended doses.
It is advisable to carry out an evaluation of electrolytes eg, sodium, potassium, chloride and carbon dioxide, creatinine and hemogram every 4 hrs. It is recommended that the patients in treatment with Potassium Citrate follow a diet without salt and increase the intake of
Slight gastrointestinal disorders may appear which can be palliated by means of concomitant administration with food.
Potassium Citrate must not be administered to patients receiving potassium-sparing diuretics (triamterene, spironolactone or amiloride).
Store at temperatures not exceeding 30°C away from light and moisture.
A12BA02 - potassium citrate ; Belongs to the class of potassium-containing preparations. Used as dietary supplements.